Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eribulin mesylate - Eisai Co Ltd

Drug Profile

Eribulin mesylate - Eisai Co Ltd

Alternative Names: B-1939; B-1939 mesylate; E-7386; E-7389; ER-086526; Eribrin; Halaven; NSC-707389; TECERIS

Latest Information Update: 25 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Co Ltd; Harvard University
  • Developer Academic and Community Cancer Research United; Asan Medical Center; Big Ten Cancer Research Consortium; Eisai Co Ltd; Emory University; Icahn School of Medicine at Mount Sinai; Merck & Co; National Cancer Center Hospital East; National Cancer Institute (USA); Pfizer; PIQUR Therapeutics; PRISM Pharma Co
  • Class 2 ring heterocyclic compounds; Antineoplastics; Cyclic ethers; Furans; Ketones; Macrocyclic compounds; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cadherin modulators; Receptor protein-tyrosine kinase modulators; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Soft tissue sarcoma
  • Phase III Non-small cell lung cancer
  • Phase II Ewing's sarcoma; Haemangioendothelioma; Haemangiosarcoma
  • Phase I/II Bladder cancer; Solid tumours
  • Phase I Colorectal cancer; Liver cancer; Ovarian cancer; Urogenital cancer
  • Discontinued Prostate cancer

Most Recent Events

  • 20 Sep 2019 Eribulin mesylate market licensed to Mylan in India
  • 31 Jul 2019 Eisai completes a phase I/II trial in Breast cancer (Combination therapy, First-line therapy, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT02513472)
  • 18 Jul 2019 Registered for Breast cancer (Metastatic disease, Second-line therapy or greater, Locally recurrent, Late-stage disease) in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top